Skip to main content

Advertisement

Table 3 Pooled results of side effects in patients during treatment

From: Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials

Studies Variables No. of studies No. of subjects Meta-analysis Model Test of heterogeneity
OR (95% CI) p value I2 p value
Studies included non-metastatic esophageal cancer Diarrhea 2 577 2.07 [1.01, 4.25] 0.05* F 0 0.35
Nausea 2 577 0.84 [0.48, 1.46] 0.53 F 16% 0.28
Emesis 2 577 0.90 [0.48, 1.70] 0.75 F 4% 0.31
Fatigue 2 577 1.22 [0.78, 1.92] 0.38 F 0 0.47
Neuropathy 2 577 0.69 [0.30, 1.56] 0.37 F 0 0.45
Rash 2 577 16.91 [3.20, 89.42] 0.0009* F 0% 0.57
Cardiac disorders 3 877 2.28 [0.78, 6.62] 0.13 F 0 0.47
Metabolic/laboratory 2 577 1.78 [0.91, 3.51] 0.09 R 58% 0.12
Dyspnoea 2 577 1.74 [0.62, 4.88] 0.29 F 28% 0.24
Infection 2 577 1.48 [0.80, 2.74] 0.21 F 43% 0.19
Vascular disorders 2 543 1.61 [0.82, 3.17] 0.17 F 38% 0.20
Acute kidney injury 2 619 1.38 [0.31, 6.25] 0.67 F 0 0.84
Dysphagia 2 619 0.88 [0.51, 1.53] 0.65 F 0 0.97
Studies included metastatic esophageal cancer Rash 2 142 5.50 [2.14, 14.14] 0.0004* R 92% 0.0004
  1. Abbreviations: OR odds ratio, F fixed effects model, R random-effects model, CI confidence interval
  2. *Statistically significant values (p ≤ 0.05), favors CET free